Back to top
more

BioXcel Therapeutics (BTAI)

(Delayed Data from NSDQ)

$2.55 USD

2.55
244,513

-0.04 (-1.54%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $2.55 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

BioXcel Therapeutics, Inc. [BTAI]

Reports for Purchase

Showing records 1 - 20 ( 107 total )

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/18/2024

Company Report

Pages: 5

Pivotal Trial Program Clarity; 2023 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

02/06/2024

Company Report

Pages: 5

Dexmedetomidine Oromucosal Formulation Patent Allowance; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

12/13/2023

Company Report

Pages: 5

Virtual Neuroscience RD Day Showcases Neurology Pipeline; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/15/2023

Company Report

Pages: 5

BXCL501 Clinical Pathway Clarified; Debt Agreements Updated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

11/07/2023

Company Report

Pages: 5

NIDA Requests Opioid Use Disorder Trial Expansion; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

10/31/2023

Company Report

Pages: 5

IGALMI Assigned Permanent J-Code; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

10/26/2023

Company Report

Pages: 5

TRANQUILITY II Data Integrity Affirmed in Third Party Audit; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

10/11/2023

Company Report

Pages: 5

BXCL701 Phase 2 Prostate Cancer Data Prove Positive; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

09/13/2023

Company Report

Pages: 5

Sublingual Dexmedetomidine Patent Estate Strengthened; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

09/08/2023

Company Report

Pages: 5

Type C Meeting Scheduled; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/28/2023

Company Report

Pages: 5

BXCL501 TRANQUILITY Program Type B Meeting Scheduled; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/18/2023

Company Report

Pages: 5

Commercial Strategy Retooled; 2Q23 Financials; Lowering PT to $11

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

07/03/2023

Company Report

Pages: 5

Positive TRANQUILITY II Data Marred by Reporting Issues; Lowering PT to $60

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

05/30/2023

Company Report

Pages: 5

BXCL501 SERENITY III Part 1 Data Look Favorable, in Our View; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

05/17/2023

Company Report

Pages: 5

BXCL501 Phase 1 Trial Data Proves Positive; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

05/11/2023

Company Report

Pages: 5

Top and Bottom-Line Miss, But All Eyes on Data Readouts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

03/21/2023

Company Report

Pages: 5

IGALMI Slow Burn Likely; 2022 Financials; Lowering PT to $66

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

02/27/2023

Company Report

Pages: 5

BXCL701 Mechanism of Action Intrigues; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

02/21/2023

Company Report

Pages: 5

Favorable BXCL701 Proof-of-Concept Clinical Data; Raising PT to $79

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

01/03/2023

Company Report

Pages: 5

TRANQUILITY and SERENITY Pivotal Trials Advance; Adjusting PT to $73

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party